guid focu new product
forecast revenu con y/i driven larg lower
gener sale north america ep estim con assum full
year opex low end guidanc rang made follow notabl chang
estim lower g-copaxon due earlier-than-expect mnta/nv
approv like third gener sometim model steeper declin
north america gener given industri trend modestli increas estim ab-
rate g-advair estim base recent competitor po vs base
revis ev/ebtida multipl vs reiter neutral balanc forward outlook
sever move part guidanc
earlier year reiter confid reach ep level vs
bofaml con see three major move part within
guidanc copaxon prescript share date modest least one
addit entrant enter lucr market wed expect
management assum share price least pre-gener level
epipen con call sale vs street seem
conserv given market share stabil howev wed expect guidanc factor
competit substitut gener key wildcard generic/biosimilar
approv advair restasi neulasta wed expect management forecast risk-adj
contribut tax rate unlik variabl management see reform rel neutral
focu area call
topic discuss gener advair us brand statu us applic
possibl approv prior mid-jun action date competitor
sandoz hikma suffer regulatori delay chanc g-
advair supplier model risk-adj sale assum
probabl success launch us gener outlook price eros
meda eu provid first look y/i perform biosimilar neulasta
market respond set potenti
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
global pharmaceut compani
develop manufactur market
pharmaceut product span three segment
gener over-the-count brand specialti
product north american biggest market
account approxim total
sale follow europ
remaind rest world becom
one largest specialti gener player
combin organ growth
number signific acquisit
neutral balanc
invest posit neg stock
like prospect organ growth us
copaxon potenti upsid gener
approv advair restasi convers
concern around headwind gener
busi well aggress assumpt
compani guidanc impli cost
cut deal may may drive
long-term valu sharehold
exhibit
price object po base multipl ebitda
rel gener peer believ share trade similar
multipl gener peer lower closest peer teva latter
benefit low trough year uptick clinic de-risk spec brand
furthermor less visibl earn profil view
compani gener growth driver less durabl sourc growth teva key
spec brand believ dcf appropri valuat methodolog
littl visibl outlook beyond one two year multipl
take follow consider approv g-advair gener advair
low- mid-single-digit growth eu row busi
risk po approv g-advair greater-than-expect competit
pressur copaxon gener
jason gerberri herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
us major specialti pharmaceut coverag cluster
compani
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
